Navigation Links
Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells

LOS ANGELES Sept. 6, 2012 A team of Cedars-Sinai Heart Institute stem cell researchers today was awarded a $1.3 million grant from the California Institute of Regenerative Medicine to continue study of an experimental stem cell therapy that treats heart attack patients with heart-derived cells. Earlier this year, data from the first clinical trial of the stem cell treatment showed the therapy helped damaged hearts regrow healthy muscle.

To date, this cell therapy, developed by Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute and Mark S. Siegel Family Professor, is the only treatment shown to regenerate the injured human heart. In this therapy, human heart tissue is used to grow specialized heart stem cells, which then are injected back into the patient's heart. The new research will focus on understanding the cellular mechanisms that have produced favorable outcomes.

"We have seen encouraging results in patients with this treatment, and it has the potential to revolutionize how we treat heart attack patients," Marbn said. "This further study will allow us to better understand how it works, which we hope will lead us to even more stem-cell based treatments for the heart."

During a heart attack, clots form suddenly on top of cholesterol-laden plaques, which block the flow of blood to the heart muscle. This causes living heart tissue to die and be replaced by a scar. The larger the scar, the higher the chance of death or disability from the heart attack.

Conventional treatments aim to limit the initial injury by opening the clogged artery and prevent further harm with medications. Regenerative therapy aims to regrow healthy heart muscle and dissolve the heart tissue -- an approach that, according to a study by Marbn published in The Lancet, led to an average 50 percent reduction in scar size.

Early study by Cedars-Sinai researchers indicates that much of the benefit in the experimental therapy is due to an indirect effect of the transplanted cardiac-derived cells. These cells seem to stimulate proliferation of the surrounding undamaged heart cells -- a previously unrecognized means of cardiac regeneration in response to cell therapy.

"This is vital basic science work that we believe will ultimately open pathways to new treatments in the fight against heart disease, the leading cause of premature death and disability," Marbn said.

The process to grow the cardiac-derived stem cells involved in the study was developed by Marbn when he was on the faculty of Johns Hopkins University. The university has filed for a patent on that intellectual property, and has licensed it to a company in which Dr. Marbn has a financial interest.

Bringing together researchers, physician scientists and clinicians, providing true "bench to bedside" advances in regenerative medicine has been a major focus of Cedars-Sinai, through both the Heart Institute and the Cedars-Sinai Regenerative Medicine Institute, led by Clive Svendsen, PhD, director.


Contact: Sally Stewart
Cedars-Sinai Medical Center

Related medicine news :

1. Cedars-Sinai stroke team earns award for improving regions quality of care
2. Cedars-Sinai physician definitively links irritable bowel syndrome and bacteria in gut
3. Cedars-Sinai researchers, with stem cells, advance understanding of spinal muscular atrophy
4. Cedars-Sinai Medical Center studies galaxy-exploring camera in the operating room
5. Cedars-Sinai awarded $17.8 million grant to develop ALS treatment
6. In war with superbugs, Cedars-Sinai researchers see new weapon: Immune-boosting vitamin
7. Witnessing, Experiencing Traumatic Events May Worsen Heart Disease
8. Risk of suicide and fatal heart attack immediately following a cancer diagnosis
9. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
10. In children born with severe heart defect, surgical management has little effect on neuro outcomes
11. Invasive heart test being dramatically overused, Stanford study shows
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
Breaking Medicine Technology: